These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 28326189)

  • 21. Tofacitinib in Combination With Conventional Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Randomized Controlled Trial.
    Strand V; Kremer JM; Gruben D; Krishnaswami S; Zwillich SH; Wallenstein GV
    Arthritis Care Res (Hoboken); 2017 Apr; 69(4):592-598. PubMed ID: 27565000
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of secukinumab on patient-reported outcomes in patients with active psoriatic arthritis in a randomised phase 3 trial.
    Strand V; Kaeley GS; Bergman MJ; Gladman DD; Coates LC; Sherif B; Hur P; Parikh B; Gilloteau I; Mease PJ
    Lancet Rheumatol; 2022 Mar; 4(3):e208-e219. PubMed ID: 38288937
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs.
    Strand V; Kremer J; Wallenstein G; Kanik KS; Connell C; Gruben D; Zwillich SH; Fleischmann R
    Arthritis Res Ther; 2015 Nov; 17():307. PubMed ID: 26530039
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of tofacitinib on fatigue, sleep, and health-related quality of life in patients with rheumatoid arthritis: a post hoc analysis of data from Phase 3 trials.
    Bartlett SJ; Bingham CO; van Vollenhoven R; Murray C; Gruben D; Gold DA; Cella D
    Arthritis Res Ther; 2022 Apr; 24(1):83. PubMed ID: 35382883
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patient-Reported Outcomes in Psoriatic Arthritis Patients with an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drugs: SELECT-PsA 2.
    Strand V; Van den Bosch F; Ranza R; Leung YY; Drescher E; Zueger P; Saffore CD; Lertratanakul A; Lippe R; Nash P
    Rheumatol Ther; 2021 Dec; 8(4):1827-1844. PubMed ID: 34661885
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-Effectiveness of Sarilumab Added to Methotrexate in the Treatment of Adult Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors.
    Muszbek N; Proudfoot C; Fournier M; Chen CI; Kuznik A; Kiss Z; Gal P; Michaud K
    J Manag Care Spec Pharm; 2019 Nov; 25(11):1268-1280. PubMed ID: 31663465
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of sarilumab pharmacodynamic and predictive markers in patients with inadequate response to TNF inhibition: a biomarker substudy of the phase 3 TARGET study.
    Gabay C; Msihid J; Zilberstein M; Paccard C; Lin Y; Graham NMH; Boyapati A
    RMD Open; 2018; 4(1):e000607. PubMed ID: 29556418
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis.
    Emery P; Blanco R; Maldonado Cocco J; Chen YC; Gaich CL; DeLozier AM; de Bono S; Liu J; Rooney T; Chang CH; Dougados M
    RMD Open; 2017; 3(1):e000410. PubMed ID: 28405473
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond.
    Strand V; de Vlam K; Covarrubias-Cobos JA; Mease PJ; Gladman DD; Chen L; Kudlacz E; Wu J; Cappelleri JC; Hendrikx T; Hsu MA
    RMD Open; 2019; 5(1):e000808. PubMed ID: 30713722
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High levels of interleukin-6 in patients with rheumatoid arthritis are associated with greater improvements in health-related quality of life for sarilumab compared with adalimumab.
    Strand V; Boklage SH; Kimura T; Joly F; Boyapati A; Msihid J
    Arthritis Res Ther; 2020 Oct; 22(1):250. PubMed ID: 33081825
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study.
    Keystone EC; Taylor PC; Tanaka Y; Gaich C; DeLozier AM; Dudek A; Zamora JV; Cobos JAC; Rooney T; Bono S; Arora V; Linetzky B; Weinblatt ME
    Ann Rheum Dis; 2017 Nov; 76(11):1853-1861. PubMed ID: 28798049
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of tocilizumab administered intravenously or subcutaneously on patient-reported quality-of-life outcomes in patients with rheumatoid arthritis.
    Strand V; Michalska M; Birchwood C; Pei J; Tuckwell K; Finch R; Kivitz AJ; Smolen JS; Burmester GR
    RMD Open; 2018; 4(1):e000602. PubMed ID: 29955380
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment.
    Schiff M; Takeuchi T; Fleischmann R; Gaich CL; DeLozier AM; Schlichting D; Kuo WL; Won JE; Carmack T; Rooney T; Durez P; Shaikh S; Hidalgo RP; van Vollenhoven R; Zerbini CAF
    Arthritis Res Ther; 2017 Sep; 19(1):208. PubMed ID: 28923098
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sarilumab monotherapy or in combination with non-methotrexate disease-modifying antirheumatic drugs in active rheumatoid arthritis: A Japan phase 3 trial (HARUKA).
    Kameda H; Wada K; Takahashi Y; Hagino O; van Hoogstraten H; Graham N; Tanaka Y
    Mod Rheumatol; 2020 Mar; 30(2):239-248. PubMed ID: 31268376
    [No Abstract]   [Full Text] [Related]  

  • 35. Impact of tocilizumab monotherapy on patient-reported outcomes in patients with rheumatoid arthritis from two randomised controlled trials.
    Strand V; Michalska M; Birchwood C; Pei J; Tuckwell K; Finch R; Gabay C; Kavanaugh A; Jones G
    RMD Open; 2017; 3(2):e000496. PubMed ID: 28955499
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Indirect Treatment Comparison of the Efficacy and Safety of Sarilumab Monotherapy in Rheumatoid Arthritis Patients with Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs.
    Choy E; Freemantle N; Proudfoot C; Chen CI; Pollissard L; Kuznik A; van Hoogstraten H; Mangan E; Carita P; Huynh TM
    Adv Ther; 2019 Apr; 36(4):817-827. PubMed ID: 30864105
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patient- and physician-reported outcomes from two phase 3 randomized studies (RAJ3 and RAJ4) of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis.
    Tanaka Y; Takeuchi T; Izutsu H; Kaneko Y; Kato D; Fukuda M; Rokuda M; Schultz NM
    Arthritis Res Ther; 2021 Aug; 23(1):221. PubMed ID: 34429152
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Budget impact analysis of sarilumab for the treatment of rheumatoid arthritis in patients with an inadequate response to conventional synthetic DMARD or TNF inhibitor therapies.
    Ferrufino CP; Munakata J; Wei W; Proudfoot C; Kuznik A; Boklage SH; Chen CI
    Clinicoecon Outcomes Res; 2018; 10():805-819. PubMed ID: 30532571
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study.
    Strand V; Burmester GR; Ogale S; Devenport J; John A; Emery P
    Rheumatology (Oxford); 2012 Oct; 51(10):1860-9. PubMed ID: 22753773
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Maintenance of Patient-Reported Outcomes in Baricitinib-Treated Patients with Moderate-to-Severe Active Rheumatoid Arthritis: Post Hoc Analyses from Two Phase 3 Trials.
    Sholter D; Wu J; Jia B; Zhang H; Griffing K; Birt J; Reis PJS; Liu H; Bingham CO
    Rheumatol Ther; 2022 Apr; 9(2):541-553. PubMed ID: 34990002
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.